Carlos R. Bachier, MD
Even with recent significant advances in the treatment of hematologic malignancies, such as chimeric antigen receptor (CAR) T-cell therapy, investigators are still focused on improving one of the field’s longest-established therapies—stem cell transplant.
State of the Science Summit™ on Hematologic Malignancies, Bachier, program director of Sarah Cannon Center for Blood Cancer, Sarah Cannon Research Institute, discussed the evolution of stem cell transplantation as a treatment for patients with hematologic malignancies.
OncLive: Please discuss the evolution of stem cell transplants.
There has been an evolution in the way that we treat transplant patients. Forty or 50 years ago, we started just using bone marrow as the source of stem cells. Now, we can obtain stem cells from the peripheral blood. This has benefited patients in the autologous setting, where the recovery of blood counts is much faster. It is the same in the allogeneic setting, where we use donors.
... to read the full story